FINHUB Insights

AMGN · Q2 FY25 · Apr 1 – Jun 30, 2025

Amgen Q2 FY25: where the revenue came from and where it went

Amgen Q2 FY25: revenue $9.2B (+9% year over year). Net profit $1.4B. Largest cohort Other $3.4B. The whole income statement as a sankey diagram from the SEC filing.

Period
Apr 1 – Jun 30, 2025
Reported
Aug 6, 2025 10-Q
Sankey diagram of Amgen's income statement for Q2 FY25: revenue of $9.2 billion splits into segments and flows out into costs, taxes and net profit.

Tap the diagram to enlarge · figures in billions of dollars

Revenue$9.2B +9% year over year
Gross profit$6.2B 67% margin
Operating profit$2.7B 29% margin
Net profit$1.4B 16% margin

The numbers

All figures in billions of U.S. dollars, for Q2 FY25 (period ends Jun 30, 2025).
ItemValueShare of revenueYear over year
Revenue 9.2 100% +9%
Other 3.4 37%
Other Products 1.7 18% +27%
Prolia 1.1 12% −4%
Repathaevolocumab 0.7 8% +31%
Otezla 0.6 7% +14%
Enbrel 0.6 7% −34%
Xgeva 0.5 5% −5%
EVENITY 0.5 5% +32%
Cost of revenue−333%
Gross profit6.267% margin+6pp
SG&A−1.718%−3pp
Other−1.820%+0pp
Operating profit2.729% margin+6pp
Tax−0.1
Interest & other costs−1.2
Net profit1.416%+7pp
Filing on EDGAR More quarters of AMGN

Source of the numbers: structured XBRL data from the filing (10-Q). The diagram is generated automatically and checked against EDGAR before release. How we calculate it → About and methodology.

Older quarters